Formononetin enhances the antitumor effect of H22 hepatoma transplanted mice.
- Author:
Mi LI
1
;
Chengzhi JIANG
2
;
Jianting CHEN
3
;
Junyan WANG
3
Author Information
1. Department of Physiology, School of Basic Medicine, Shaanxi University of Traditional Chinese Medicine, Xianyang 712046, China.
2. Department of Gastroenterology, Second Affiliated Hospital of Xi'an Medical College, Xi'an 710038, China.*Corresponding author, E-mail: 40265298@qq.com.
3. Department of Gastroenterology, Second Affiliated Hospital of Xi'an Medical College, Xi'an 710038, China.
- Publication Type:Journal Article
- MeSH:
Male;
Animals;
Mice;
Carcinoma, Hepatocellular/pathology*;
Liver Neoplasms/genetics*;
Interleukin-10/genetics*;
B7-H1 Antigen;
Granzymes/genetics*;
Programmed Cell Death 1 Receptor/metabolism*;
CD8-Positive T-Lymphocytes/metabolism*;
Mice, Inbred C57BL;
Transforming Growth Factor beta/genetics*;
RNA, Messenger/metabolism*;
Forkhead Transcription Factors/genetics*;
Cell Line, Tumor
- From:
Chinese Journal of Cellular and Molecular Immunology
2023;39(12):1063-1068
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of formononetin on immunity of mice with transplanted H22 hepatocarcinoma. Methods Male C57BL/6 mice were subcutaneously inoculated with H22 cells (4×105) to establish a tumor-bearing mouse model. The mice were treated with formononetin [10 mg/(kg.d)] or [50 mg/(kg.d)] for 28 days, and then the tumor inhibition rate was calculated. Carrilizumab was used as a positive control drug. The expressions of CD8, granzyme B and forkbox transcription factor 3 (FOXP3) in HCC tissues were analyzed by immunohistochemical staining. The mRNA and protein expression of programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) in HCC tissues were detected by real-time PCR or Western blot analysis, respectively. The serum levels of interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) were detected by ELISA. Results Formononetin increased the tumor inhibition rate and the positive rate of CD8 and granzyme B staining in tumor-bearing mice. There was no significant difference in the positive rate of FOXP3 staining in tumor tissues of mice in each group. Formononetin decreased the levels of IL-10 and TGF-β in serum of tumor-bearing mice, and decreased the relative expression of mRNA and protein of PD-1 and PD-L1 in tumor tissue of tumor-bearing mice. Conclusion Formononetin can activate CD8+ T cells and reduce the release of immunosuppressive factors in regulatory T cells by blocking PD-1/PD-L1 pathway and play an antitumor role.
